Phase @b was an open-label , dose de-escalation study to identify a safe dose of rilotumumab ( initial dose @ mg/kg intravenously on day @ ) plus ECX ( epirubicin @ mg/m ( @ ) intravenously on day @ , cisplatin @ mg/m ( @ ) intravenously on day @ , capecitabine @ mg/m ( @ ) twice a day orally on days @-@ , respectively ) , administered every @ weeks .